Chronic myelogenous leukemia

Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type

Article metrics


Chronic myeloid leukemia is driven by a hybrid gene, BCR-ABL1, that codes for a leukemogenic tyrosine kinase (TK) protein of 210 KDa (p210BCR-ABL1). Resistance to TK inhibitor (TKI) therapy occurs in relatively few patients, no more than 10%, while persistence of minimal residual disease during TKI therapy occurs in the great majority of patients. Resistance is a cause of death, persistence is compatible with a fairly normal length and quality of life, but may require lifelong treatment. The causes of resistance are heterogeneous, including the development of other genomic abnormalities or the altered expression of other genes, requiring different treatments. The causes of persistence may not be the same as those of resistance. We hypothesize that the variability in breakpoint position within the Major-breakpoint cluster region (M-bcr), resulting in two different messenger RNAs that may or may not include exon 14 of BCR (e13a2 and e14a2, respectively), and, as a consequence, in two p210BCR-ABL1 proteins that differ by 25 amino acids, may be a cause of persistence. The hypothesis is based on a critical review of the relationships between the BCR-ABL1 transcript types, the response to TKIs, the outcome of treatment, and the immune response, suggesting that the e14a2 transcript is associated with more and deeper molecular responses, hence with a higher probability of achieving treatment-free remission (TFR). Investigating this putative cause of persistence may help bringing more patients into stable TFR.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1


  1. 1.

    Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini D, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

  2. 2.

    Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823–31.

  3. 3.

    Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukemia in the tyrosine-kinase inhibitor era: analysis of patients data from six prospective trials. Lancet Hematol. 2015;2:e186–e193.

  4. 4.

    Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol.2016;34:2851–7.

  5. 5.

    Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Clinical practice guidelines in oncology. Chronic Myeloid Leukemia version 1.2019. National Comprehensive Cancer Center. Network. 2018;16:1108–35.

  6. 6.

    Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33:1543–56.

  7. 7.

    Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23.

  8. 8.

    Saussele S, Richter J, Hochhaus A, Mahon F-X. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–47.

  9. 9.

    Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208–15.

  10. 10.

    Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–20.

  11. 11.

    Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84.

  12. 12.

    Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17:49.

  13. 13.

    Mahon F-X, Deininger MW, Schulteis B, Chabrol G, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070–9.

  14. 14.

    Mahon F-X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101:2368–73.

  15. 15.

    White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064–72.

  16. 16.

    Eadie LN, Hughes TP, White DL. Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitors therapy. Leukemia. 2018;32:2288–91.

  17. 17.

    Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, et al. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica. 2018;103:2026–32.

  18. 18.

    Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, et al. High BCR-ABL/GUSIS levels at diagnosis of chronic phase CML are associated with unfavourable responses to standard-dose imatinib. Clin Cancer Res. 2017;23:7189–98.

  19. 19.

    Ercaliskan A, Eskazan E. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer. 2018;124:3806–18.

  20. 20.

    Mills KL, Mackenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood. 1988;72:1237–41.

  21. 21.

    Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019;33:1173–83.

  22. 22.

    The ICSG on CML. Chronic myeloid leukemia, BCR/ABL transcript, response to α-interferon, and survival. Leukemia. 1995;9:1648–51.

  23. 23.

    Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99:1441–7.

  24. 24.

    Sasaki K, Kantarjian H, O’Brien S, Ravandi FF, Konopleva M, Borthakur G, et al. Predictions for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018;124:1160–8.

  25. 25.

    D’Adda M, Farina M, Schieppati F, Cerqui E, Ruggeri G, Ferrari S, et al. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer. 2019.

  26. 26.

    Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated front-line with imatinib. Am J Hematol. 2017;92:797–805.

  27. 27.

    Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, et al. Chronic myeloid leukaemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94:1362–7.

  28. 28.

    Jain P, Kantarjian H, Patel KP, Nogueras Gonzales G, Luthra R, Shamanna RK, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127:1269–75.

  29. 29.

    Pagnano KBB, Miranda EC, Delamain MT, Duarte GO, de Paula EV, Lorand-Metze I, et al. Influence of BCR-ABL transcript type on outcome in patients with chronic phase chronic myeloid leukemia treated with imatinib. Clin Lymphoma Myeloma Leuk. 2017;17:728–33.

  30. 30.

    Lin HX, Sjaarda J, Dyck J, Stringer R, Hillis C, Harvey M, et al. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. Eur J Haematol. 2016;96:360–6.

  31. 31.

    Castagnetti F, Gugliotta G, Breccia M, Stagno F, D’Adda M, Levato L, et al. Prognostic value of BCR-ABL1 transcript type in chronic myeloid leukemia patients treated frontline with nilotinib. Blood. 2016;128:3070.

  32. 32.

    Bonifacio M, Scaffidi L, Binotto G, De Marchi F, Maino E, Calistri E, et al. Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with standard dose imatinib: a study from the “Gruppo Triveneto LMC”. Blood. 2015;126:597.

  33. 33.

    Da Silva MS, Miranda EC, Torresan Delamain M, Olivera Duarte G, Vergilio BR, Pascoal Lopes AB, et al. B3A2 transcript is an independent factor for the achievement of a deep molecular response in chronic phase-chronic myeloid leukemia patients treated with imatinib in first line. Blood. 2018;132(S1):1749.

  34. 34.

    Shanmuganathan N, Branford S, Yong ASM, Hiwase DK, Yeung DT, Ross DM, et al. The e13a2 BCR-ABL1 transcript is associated with higher rates of molecular recurrence after treatment-free remission attempts: retrospective analysis of the Adelaide cohort. Blood. 2018;132(S1):1731.

  35. 35.

    Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomized, phase 2 trial. Lancet Haematol. 2017;4:e310–e316.

  36. 36.

    Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, et al. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol. 2017;143:843–5.

  37. 37.

    Lee S-E, Choi S-Y, Kim S-H, Song H-Y, Yoo H-L, Lee MJ, et al. Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy. Leuk Lymphoma. 2018;59:105–13.

  38. 38.

    Lauseker M, Bachi K, Turkina A, Faber E, Prejzner W, Olsson-Stromberg U, et al. Prognosis of patients with chronic myeloid leukemia diagnosed in advanced phase. Personal communication.

  39. 39.

    Lee S-E, Choi S-Y, Song H-Y, Choy SY, Song H-Y, Kim S-H, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101:717–23.

  40. 40.

    Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D’Adda M, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med. 2019;8:2041–55.

  41. 41.

    Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, et al. Observational study of chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors on clinical practice. Haematologica. 2019;104:1589–96.

  42. 42.

    Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with chronic myeloid leukemia. Blood. 2013;121:3818–24.

  43. 43.

    Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.

  44. 44.

    Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31.

  45. 45.

    Saussele S, Weisser A, Muller MC, Emgi M, La Rosée P, Paschka P, et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia. 2000;14:2006–10.

  46. 46.

    Kjaer L, Skov V, Andersen MT, Haggerholm A, Clair P, Gniot M, et al. Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Eur J Haematol. 2019;103:26–34.

  47. 47.

    Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia. 2017;31:1502–15.

  48. 48.

    Cutler J, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S, Nirujogi RS, et al. Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis. Leukemia. 2017;31:1513–24.

  49. 49.

    Gratwohl A, Brand R, Apperley J, v. Biezen A, Bandini G, Devergie A, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantation for chronic myeloid leukemia. Blood. 2002;100:3877–86.

  50. 50.

    Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, et al. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes. Blood. 2001;98:1498–505.

  51. 51.

    Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentric observational trial. Lancet. 2005;365:657–62.

  52. 52.

    Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21:2287–95.

  53. 53.

    Westermann J, Kopp J, van Lessen A, Hecker A-C, Baskaynak G, le Coutre P, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol. 2007;137:297–306.

Download references

Author information

Correspondence to Michele Baccarani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark